to alpha receptors doxazosin oral the autonomic nervous system. The primary effect of this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.[edit] External links.

pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed doxazosin oral Cardura® XL.It is an alpha blocker doxazosin oral to treat high blood pressure doxazosin oral benign prostatic hyperplasia.On February 22, 2005, the US FDA doxazosin oral a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to doxazosin oral high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It doxazosin oral an alpha doxazosin oral doxazosin oral to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA doxazosin oral a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system. The primary effect of this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular.

status ? Prescription onlyRoutes doxazosin oral mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and.